On May 18, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, reported the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held June 3–7, 2016, in Chicago (Press release, Puma Biotechnology, MAY 18, 2016, View Source [SID:1234512548]). Abstracts are available to the public online on the ASCO (Free ASCO Whitepaper) website: www.abstract.asco.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract #516: Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mut MBC)

Poster Session: Breast Cancer-HER2/ER; Sunday, June 5, 8:00–11:30 a.m. CDT, Hall A, Poster Board #4

The abstract will be included in the Poster Discussion Session: Breast Cancer—HER2/ER; Sunday, June 5, 11:30 a.m.–12:45 p.m. CDT, June 5, Hall D2